Non-small cell lung cancer
RecruitingZongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations
Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+3
Spain- Participants:18–64 years · 65+ years
- Substances:Carboplatin
